Automated and Closed Cell Therapy Processing System Market Size & Growth Forecast 2027–2036, By Segments (Workflow, Type, Scale), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Automated and Closed Cell Therapy Processing System Market size was around USD 1.9 billion in 2026 and is slated to grow at a 19.67% CAGR from 2027 to 2036, crossing USD 11.44 billion by 2036. The industry revenue for 2027 is assessed at USD 2.21 billion.
Get more details on this report
Request Free Sample ReportAutomated and Closed Cell Therapy Processing System Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to its established cell therapy ecosystem, specialized manufacturing infrastructure, and demand for automated, closed workflows that improve consistency while reducing contamination risk.
- Asia Pacific is projected to expand at a 22.18% CAGR, supported by accelerating cell therapy development and increasing adoption of automated manufacturing platforms for greater process control and scalability.
Segment Momentum
- Separation held a 33.62% share in 2026 because it is essential for achieving cell purity, consistency, and contamination control while supporting reliable downstream processing in automated manufacturing environments.
- Non Stem Cell Therapy is growing fastest because automated closed processing systems improve scalability, reduce operator intervention, and deliver the process consistency required for complex cell therapy manufacturing.
Market Expansion Drivers
- Rising regenerative medicine adoption accelerating demand for automated closed-loop cell therapy manufacturing.
- Increasing investments in scalable contamination-free cell processing platforms supporting commercial therapy expansion.
- Expanding integration of AI-enabled process monitoring improving cell therapy production efficiency and standardization.
Leading Market Participants
- Prominent players in the automated and closed cell therapy processing system market include Miltenyi Biotec B.V. & Co. KG (Germany), Lonza Group AG (Switzerland), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (United States), Danaher Corporation (United States), Fresenius Kabi AG (Germany), Terumo Corporation (Japan), ThermoGenesis Holdings, Inc. (United States), BioSpherix, Ltd. (United States), Cellares Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.9 billion
- 2027 Estimated Market Size: USD 2.21 billion.
- Projected Market Size: USD 11.44 billion by 2036
- Growth Forecast: 19.67% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Separation (Workflow) | Non Stem Cell Therapy (Type) | Pre-Commercial/R&D Scale (Scale)
- Emerging Opportunity Segment: Separation (Workflow) | Non Stem Cell Therapy (Type) | Commercial Scale (Scale)
Market Growth Drivers and Industry Trends
Rising regenerative medicine adoption accelerating demand for automated closed-loop cell therapy manufacturing
The expanding development and adoption of regenerative medicine is increasing the need for manufacturing platforms capable of producing cell-based therapies consistently and efficiently, supporting the automated and closed cell therapy processing system market. Automated closed-loop systems can reduce manual handling and limit exposure of cellular materials to external environments during processing. Their ability to integrate multiple production steps within controlled workflows is particularly valuable as cell therapy manufacturing moves toward more standardized and scalable production practices.
Increasing investments in scalable contamination-free cell processing platforms supporting commercial therapy expansion
Greater investment in cell therapy manufacturing infrastructure is encouraging the deployment of scalable processing technologies that can maintain controlled production conditions as therapy volumes increase. The automated and closed cell therapy processing system market benefits from demand for platforms that minimize contamination risks while improving process consistency and operational control. Closed processing environments can reduce direct intervention during critical manufacturing steps, while scalable system configurations allow producers to adapt workflows to expanding commercial production requirements.
Expanding integration of AI-enabled process monitoring improving cell therapy production efficiency and standardization
The incorporation of artificial intelligence into manufacturing oversight is creating new capabilities for real-time process analysis, supporting the automated and closed cell therapy processing system market through improved production monitoring and standardization. AI-enabled systems can analyze process data, identify deviations, and support more consistent control of critical manufacturing parameters. Greater visibility into production conditions can help operators detect process variations earlier and optimize workflows across complex cell therapy manufacturing operations.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising regenerative medicine adoption accelerating demand for automated closed-loop cell therapy manufacturing | 2.00% | High | North America, Europe | High | Near Term |
| Increasing investments in scalable contamination-free cell processing platforms supporting commercial therapy expansion | 1.80% | Moderate | Asia Pacific, North America | High | Mid Term |
| Expanding integration of AI-enabled process monitoring improving cell therapy production efficiency and standardization | 1.40% | Moderate | Asia Pacific, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America led the automated and closed cell therapy processing system market in 2026, benefiting from a highly developed cell and gene therapy ecosystem, advanced bioprocessing infrastructure, and strong demand for technologies that improve manufacturing consistency and process control. The growing complexity of cell-based therapies is increasing the need for automated platforms capable of reducing manual intervention, limiting contamination risks, and improving reproducibility across processing workflows. Research institutions, specialized treatment centers, and biopharmaceutical manufacturing facilities are also placing greater emphasis on scalable and standardized production approaches. These conditions, together with established regulatory and technical capabilities, support the region's strong adoption of closed and automated processing technologies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market as investments in biotechnology, advanced healthcare infrastructure, and cell therapy research continue to expand. Growing clinical and research activity is increasing the need for reliable processing systems that can support more sophisticated cell-based applications while maintaining controlled manufacturing environments. Healthcare modernization and the development of specialized biotechnology facilities are creating additional opportunities for automation and closed-system technologies. Regional stakeholders are also increasingly focused on improving production efficiency, quality consistency, and operational scalability, encouraging a shift away from labor-intensive processing methods and supporting stronger demand for advanced cell therapy processing platforms.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
GMP Process IntegrationGermany emphasizes automated and closed processing technologies that strengthen quality assurance within cell therapy manufacturing facilities. Organizations in Germany continue investing in systems that improve reproducibility, contamination control, and efficient GMP-compliant production operations.
France 🇫🇷
Quality-Controlled ProductionFrance promotes automated and closed cell therapy processing systems that improve manufacturing quality and operational efficiency. Research organizations and manufacturers in France increasingly adopt integrated platforms that streamline production while supporting stringent quality management practices.
Italy 🇮🇹
Translational Manufacturing SupportItaly is advancing automated and closed cell therapy processing through stronger collaboration between research institutions and specialized manufacturing facilities. Equipment suppliers in Italy emphasize flexible, contamination-controlled systems that facilitate efficient technology transfer into clinical production environments.
Japan 🇯🇵
Advanced Bioprocess AutomationJapan prioritizes automated cell therapy processing systems that enhance manufacturing precision and operational reliability. Companies in Japan increasingly integrate closed-platform technologies that support standardized production while minimizing process variability across clinical and commercial applications.
South Korea 🇰🇷
Commercial Manufacturing ReadinessSouth Korea continues expanding automated and closed cell therapy processing capabilities to support growing commercial manufacturing requirements. Technology providers focus on flexible platforms that improve production efficiency, simplify scale-up activities, and strengthen manufacturing consistency.
United States 🇺🇸
Scalable Cell ManufacturingThe U.S. automated and closed cell therapy processing system market is driven by efforts to scale commercial cell therapy manufacturing while maintaining process consistency. Developers increasingly adopt automated platforms that reduce manual intervention and support regulatory compliance throughout production workflows.
Segment Leadership and Growth Trends
Automated and Closed Cell Therapy Processing System Market Share (%), by Workflow, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWorkflow Segment Analysis: Separation (Largest & Fastest-Growing Segment)
In the automated and closed cell therapy processing system market, the separation workflow segment held the largest share of 33.62% in 2026 and is also the fastest-growing segment. Separation is a fundamental stage in cell therapy processing because it enables the selective isolation, concentration, or removal of specific cellular components required for subsequent manufacturing steps. Increasing demand for consistent cell populations, improved process control, and reduced manual intervention is encouraging the adoption of automated separation technologies. Closed processing environments also help limit contamination risks and improve reproducibility, strengthening the importance of separation within advanced cell therapy workflows.
Type Segment Analysis: Non Stem Cell Therapy (Largest & Fastest-Growing Segment)
The non stem cell therapy segment led the market in 2026 and is also expected to represent the fastest-growing type segment. Its strong position reflects the expanding development and processing requirements associated with cell-based therapies that use differentiated or other non-stem cell populations. Increasing investment in advanced therapeutic modalities is creating demand for processing platforms capable of handling complex cellular materials with greater consistency and scalability. Automation and closed-system processing can further improve workflow standardization, minimize operator-dependent variability, and support the transition of cell therapies toward more efficient clinical and commercial manufacturing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Workflow | Separation, Expansion, Apheresis, Fill- Finish, Cryopreservation, Others | Separation | Separation |
| Type | Stem Cell Therapy, Non Stem Cell Therapy | Non Stem Cell Therapy | Non Stem Cell Therapy |
| Scale | Pre-Commercial/R&D Scale, Commercial Scale | Pre-Commercial/R&D Scale | Commercial Scale |
Competitive Landscape and Market Positioning
Leading companies in the automated and closed cell therapy processing system market:
1. Miltenyi Biotec B.V. & Co. KG (Germany)
2. Lonza Group AG (Switzerland)
3. Sartorius AG (Germany)
4. Thermo Fisher Scientific Inc. (United States)
5. Danaher Corporation (United States)
6. Fresenius Kabi AG (Germany)
7. Terumo Corporation (Japan)
8. ThermoGenesis Holdings Inc. (United States)
9. BioSpherix Ltd. (United States)
10. Cellares Corporation (United States)
The automated and closed cell therapy processing system market is evolving with increasing adoption of automation in bioprocessing workflows. Enhanced system integration is improving consistency and scalability in cell therapy production. Continuous development of advanced processing platforms is supporting faster and safer therapeutic manufacturing, while innovation-driven ecosystems are accelerating adoption across regenerative medicine applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Miltenyi Biotec B.V. & Co. KG (Germany) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Sartorius AG (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Danaher Corporation (United States) | |||||||
| Fresenius Kabi AG (Germany) | |||||||
| Terumo Corporation (Japan) | |||||||
| ThermoGenesis Holdings Inc. (United States) | |||||||
| BioSpherix Ltd. (United States) | |||||||
| Cellares Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Limula | Jun-26 | Limula officially transitioned to the commercial phase, securing its first revenues and a pipeline of 8 biotech/clinical customers. The company successfully completed a fully automated, 7-day, end-to-end CAR-T cell production run on its "LimONE" device, achieving over 40-fold cell expansion with high viability, outperforming industry gold-standard solutions. |
| Limula | Jun-26 | To support its transition from a research-driven startup to a commercial manufacturing entity, Limula appointed Thomas Eaton as the new CEO. The leadership change is focused on scaling industrial production of the LimONE platform and solidifying the company’s manufacturing readiness to meet clinical demands for personalized cancer treatments. |
| ProPharma & PBL | May-24 | ProPharma and PBL launched the "Cell Factory Box" (CF Box), an automated, closed-system device designed for cell and gene therapy manufacturing. The platform provides a scalable, GMP-compliant environment that minimizes human intervention, reducing the risk of contamination and enhancing the efficiency of producing high-value personalized therapies. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Automated and Closed Cell Therapy Processing System Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapy Source | Autologous Cell Therapy, Allogeneic Cell Therapy |
| Manufacturing Model | Centralized Manufacturing, Decentralized Manufacturing, Hybrid Manufacturing |
| End User | Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic and Research Institutions, Hospitals and Cell Therapy Centers |
Automated and Closed Cell Therapy Processing System Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Cell Therapy Manufacturing Scalability Assessment |
|
| Automated Processing Workflow Adoption Analysis |
|
| Outsourcing & Partnership Opportunity Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the automated and closed cell therapy processing system market?
What is the projected value of the automated and closed cell therapy processing system industry by 2036?
How is regenerative medicine adoption influencing demand for automated closed cell therapy processing systems?
How are AI-enabled monitoring systems improving cell therapy manufacturing efficiency?
Why is Separation the leading workflow segment in the automated and closed cell therapy processing system market?
Why is Non Stem Cell Therapy the fastest-growing type segment in the automated and closed cell therapy processing system market?
Why does North America lead the automated and closed cell therapy processing system market?
What is driving rapid growth in the automated and closed cell therapy processing system market in Asia Pacific?
Who are the leading players in the automated and closed cell therapy processing system landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization